Market Overview

BIO Applauds Advancement of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018

Share:

Legislation would strengthen the pipeline and stockpile of medical
countermeasures vital to our nation's safety and defense

The Biotechnology Innovation Organization (BIO) applauds the House
Energy and Commerce Committee for voting this week to advance the
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of
2018 (H.R. 6378). The legislation would re-authorize critical federal
biodefense programs and agencies, including the BioShield Special
Reserve Fund (SRF), the Biomedical Advanced Research and Development
Authority (BARDA), and the Strategic National Stockpile (SNS).

"Over the past fifteen years, federal biodefense programs and agencies
have spurred the creation of dozens of medical countermeasures, in
partnership with industry, greatly improving our nation's capacity to
prepare and respond to the countless known and unknown chemical,
biological, radiological and nuclear threats facing our nation," said
BIO President and CEO Jim Greenwood. "Yet with each passing week, the
number and scale of these threats continues to grow – whether from rogue
regimes, terrorist groups, emerging infectious diseases or pandemics."

"By authorizing increased, multi-year funding for these programs, as
well as granting BARDA authority to address pandemic influenza, emerging
infectious diseases, and antimicrobial resistance, this legislation
would provide much needed flexibility and predictability for both
government agencies as well as their private sector partners, which play
a vital role in discovering and developing the medical countermeasures
so desperately needed to protect our nation from these threats.
Investments in preparedness and medical countermeasure development will
enhance our response efforts, save lives, and be more cost effective in
an emergency."

"I applaud Congresswomen Susan Brooks (R-IN) and Anna G. Eshoo (D-CA),
along with Energy and Commerce Committee Chairman Greg Walden (R-OR) and
Ranking Member Frank Pallone (D-NJ) for their leadership and bipartisan
cooperation in advancing this vital legislation."

Background

After 9/11 and the 2001 anthrax attacks, Congress mandated a dedicated
effort to develop and stockpile drugs, vaccines and diagnostics needed
to protect the American people from chemical, biological, radiological,
nuclear (CBRN) and pandemic threats. Because medical countermeasures to
protect against threats like anthrax, Ebola, and plague have little or
no commercial market, in 2004, Congress passed the Project BioShield Act
which created the Special Reserve Fund (SRF) to help fund the
development of these products. The 2006 Pandemic and All-Hazards
Preparedness Act (PAHPA) created the position of the Assistant Secretary
for Preparedness and Response (ASPR) to lead the government's response
to national health emergencies. The bill also created the Biomedical
Advanced Research and Development Authority (BARDA) to provide industry
partners with funding and technical assistance in the advanced research
and development of medical countermeasures. Key federal programs are
reauthorized and funded every five years through the PAHPA legislation.

About BIO

BIO is the world's largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention
, the world's largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW
is BIO's blog chronicling "innovations transforming our world" and the
BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe
to the BIO Newsletter
.

Upcoming BIO Events

       

BIO
Latin America Conference

September 4-5, 2018

Sao Paulo, Brazil

   

BIO
Investor Forum

October 17-18, 2018

San Francisco

BIO
Patient and Health Advocacy Summit

October 25-26, 2018

Washington, DC

   

 

View Comments and Join the Discussion!